Anti-IL-6 monoclonal antibody
Siltuximab
Brand names: Sylvant
Adult dose
Dose: 11 mg/kg IV every 3 weeks
Route: IV
Frequency: q3w
Clinical pearls
- Multicentric Castleman's disease (HHV-8 negative, HIV negative)
- Per NICE TA664
Contraindications
- Active severe infection
- Hypersensitivity
Side effects
- Infections
- Infusion reactions
- Cytopenias
- Hyperlipidaemia
- GI perforation
- Hypertension
Interactions
- Live vaccines
- CYP substrates (IL-6 normalisation)
Monitoring
- FBC
- LFTs
- Lipids
- BP
Reference: BNF; NICE TA664; SmPC; https://bnf.nice.org.uk/drugs/siltuximab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO